


PhysioStim appoints Dr. Bruno Le Grand as scientific advisor

Minoryx’s preclinical data for leriglitazone in Friedreich’s Ataxia published in Neurobiology of Disease Journal

European Investment Bank provides Minoryx with up to €25 million to support development of breakthrough therapies in orphan neurodegenerative diseases

Tollys extends its executive management team with appointment of Bettina Werle as CSO

Amolyt Pharma annonce la première administration de l’AZP-3601 dans son essai clinique de phase 1

Advent France Biotechnology appoints Geoffroy de Ribains as operating partner

Kymos and Prolytic merge to become Kymos Group, a top pan-European CRO dedicated to innovative pharmaceuticals

Minoryx Therapeutics and Sperogenix Therapeutics enter into exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong and Macau
